A drug discovered by CHOP researchers is currently in a phase 3 clinical trial and targets the pathological process that leads to excess bone growth in FOP.

After a year of pandemic lockdowns, high school athletes are getting injured. The Philadelphia Inquirer asked CHOP experts for advice on how to safely return to play.

The Division of Oncology at Children’s Hospital of Philadelphia (CHOP) has appointed Sarah Tasian, MD, as Chief of the Section of Hematologic Malignancies.

Katsuhide Maeda, MD, PhD, has been appointed the Surgical Director for the Heart Failure and Transplant Program and the Lung Transplant Program at Children's Hospital of Philadelphia (CHOP).

Award by Philadelphia County Medical Society honors a physician who has demonstrated the most valuable contributions to surgical or medical healing.

Urgent Care Center Offers Convenient After-hours Access for Montgomery County Community.

CHOP researchers have discovered a heat-shock protein that requires the addition of a lipid particle to function, providing a roadmap for new antimalarial drugs.

The treatment modifies a domain in the CAR that targets CD19, making it look more human and therefore less likely to be rejected by patients.

Type II alveolar cells, a major cell type infected by SARS-CoV-2, possess unique immunologic properties and appear to play a role in improving the outcome of respiratory viral infections.

Separation anxiety affects 3% of children and 8% of teens. Two CHOP doctors offer tips to help both groups better adapt to changing situations.